Oncology Capex To Revenue from 2010 to 2025

TOIIW Stock  USD 0.02  0  25.00%   
Oncology Institute Capex To Revenue yearly trend continues to be fairly stable with very little volatility. Capex To Revenue will likely drop to 0.01 in 2025. Capex To Revenue is the ratio of a company's capital expenditures to its total revenue, indicating how much of the revenue is used for acquiring or maintaining physical assets. View All Fundamentals
 
Capex To Revenue  
First Reported
2010-12-31
Previous Quarter
0.0127
Current Value
0.00952
Quarterly Volatility
0.00464598
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Oncology Institute financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Oncology Institute's main balance sheet or income statement drivers, such as Depreciation And Amortization of 3.8 M, Interest Expense of 8.2 M or Selling General Administrative of 67.6 M, as well as many indicators such as Price To Sales Ratio of 0.51, Dividend Yield of 0.0235 or PTB Ratio of 2.88. Oncology financial statements analysis is a perfect complement when working with Oncology Institute Valuation or Volatility modules.
  
Check out the analysis of Oncology Institute Correlation against competitors.
For more information on how to buy Oncology Stock please use our How to Invest in Oncology Institute guide.

Latest Oncology Institute's Capex To Revenue Growth Pattern

Below is the plot of the Capex To Revenue of The Oncology Institute over the last few years. It is the ratio of a company's capital expenditures to its total revenue, indicating how much of the revenue is used for acquiring or maintaining physical assets. Oncology Institute's Capex To Revenue historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Oncology Institute's overall financial position and show how it may be relating to other accounts over time.
Capex To Revenue10 Years Trend
Slightly volatile
   Capex To Revenue   
       Timeline  

Oncology Capex To Revenue Regression Statistics

Arithmetic Mean0.01
Geometric Mean0.01
Coefficient Of Variation52.10
Mean Deviation0
Median0.01
Standard Deviation0
Sample Variance0.000022
Range0.0157
R-Value0.65
Mean Square Error0.000013
R-Squared0.43
Significance0.01
Slope0.0006
Total Sum of Squares0.0003

Oncology Capex To Revenue History

2025 0.00952
2024 0.0127
2023 0.0141
2022 0.0219
2021 0.015
2020 0.006368
2019 0.007751

About Oncology Institute Financial Statements

Oncology Institute investors use historical fundamental indicators, such as Oncology Institute's Capex To Revenue, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Oncology Institute. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Capex To Revenue 0.01  0.01 

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Oncology Stock Analysis

When running Oncology Institute's price analysis, check to measure Oncology Institute's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Oncology Institute is operating at the current time. Most of Oncology Institute's value examination focuses on studying past and present price action to predict the probability of Oncology Institute's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Oncology Institute's price. Additionally, you may evaluate how the addition of Oncology Institute to your portfolios can decrease your overall portfolio volatility.